FI20115914A0 - Modifierat onkolytiskt virus - Google Patents

Modifierat onkolytiskt virus

Info

Publication number
FI20115914A0
FI20115914A0 FI20115914A FI20115914A FI20115914A0 FI 20115914 A0 FI20115914 A0 FI 20115914A0 FI 20115914 A FI20115914 A FI 20115914A FI 20115914 A FI20115914 A FI 20115914A FI 20115914 A0 FI20115914 A0 FI 20115914A0
Authority
FI
Finland
Prior art keywords
virus vectors
vaccinia
vaccinia virus
modified oncolytic
oncolytic virus
Prior art date
Application number
FI20115914A
Other languages
English (en)
Finnish (fi)
Other versions
FI20115914L (sv
Inventor
Akseli Hemminki
Sari Pesonen
Marko Ahonen
Markus Vaehae-Koskela
Suvi Parviainen
Vincenzo Cerullo
Iulia Diaconu
Eerika Karli
Original Assignee
Akseli Hemminki
Sari Pesonen
Marko Ahonen
Markus Vaehae-Koskela
Suvi Parviainen
Vincenzo Cerullo
Iulia Diaconu
Eerika Karli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akseli Hemminki, Sari Pesonen, Marko Ahonen, Markus Vaehae-Koskela, Suvi Parviainen, Vincenzo Cerullo, Iulia Diaconu, Eerika Karli filed Critical Akseli Hemminki
Priority to FI20115914A priority Critical patent/FI20115914L/sv
Publication of FI20115914A0 publication Critical patent/FI20115914A0/sv
Priority to PCT/FI2012/050895 priority patent/WO2013038066A1/en
Publication of FI20115914L publication Critical patent/FI20115914L/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C12N15/8636—Vaccina virus vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24171—Demonstrated in vivo effect
FI20115914A 2011-09-16 2011-09-16 Modifierat onkolytiskt virus FI20115914L (sv)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FI20115914A FI20115914L (sv) 2011-09-16 2011-09-16 Modifierat onkolytiskt virus
PCT/FI2012/050895 WO2013038066A1 (en) 2011-09-16 2012-09-14 Modified oncolytic vaccinia virus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20115914A FI20115914L (sv) 2011-09-16 2011-09-16 Modifierat onkolytiskt virus

Publications (2)

Publication Number Publication Date
FI20115914A0 true FI20115914A0 (sv) 2011-09-16
FI20115914L FI20115914L (sv) 2013-03-17

Family

ID=44718819

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20115914A FI20115914L (sv) 2011-09-16 2011-09-16 Modifierat onkolytiskt virus

Country Status (2)

Country Link
FI (1) FI20115914L (sv)
WO (1) WO2013038066A1 (sv)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014037124A1 (en) * 2012-09-04 2014-03-13 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
EP3049445A4 (en) 2013-09-24 2017-10-25 Medicenna Therapeutics, Inc. Interleukin-2 fusion proteins and uses thereof
JP6378200B2 (ja) * 2013-11-21 2018-08-22 国立大学法人鳥取大学 分裂促進因子活性化タンパク質キナーゼ依存性組換えワクシニアウイルス（ｍｄ−ｒｖｖ）及びその使用
CA2946398A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
KR101845739B1 (ko) * 2014-10-08 2018-04-05 부산대학교 산학협력단 신규한 암용해 바이러스, 이의 제작 방법 및 이의 용도
CA2977660A1 (en) 2015-02-25 2016-09-15 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
CA2982896A1 (en) 2015-04-17 2016-10-20 Memorial Sloan Kettering Cancer Center Use of modified vaccinia ankara virus (mva) or mva with a deletion of virulence factor e8 as immunotherapeutic agent against solid tumors
KR20160140075A (ko) * 2015-05-29 2016-12-07 코오롱생명과학 주식회사 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터
WO2016205429A1 (en) * 2015-06-15 2016-12-22 New York University Method of treatment using oncolytic viruses
SG11201805835WA (en) 2016-01-08 2018-08-30 Replimune Ltd Modified oncolytic virus
MX2018010204A (es) 2016-02-25 2019-05-06 Memorial Sloan Kettering Cancer Center Virus de la vaccinia atenuada competentes para replicacion con la supresion de timidina quinasa con y sin la expresion del flt3l o gm-csf humanos para inmunoterapia del cancer.
MX2018010231A (es) 2016-02-25 2019-06-06 Memorial Sloan Kettering Cancer Center Mva recombinante o mvadele3l que expresa el flt3l humano y uso de los mismos como agentes inmunoterapéuticos contra tumores sólidos.
EP3515419A4 (en) * 2016-09-21 2020-06-10 Stephen H. Thorne HIGH MOBILITY GROUP 1 BOX MUTANT
CN110431228B (zh) 2016-11-02 2024-04-02 戴维·埃文斯 合成嵌合痘病毒
KR20190097240A (ko) * 2016-12-28 2019-08-20 트랜스진 에스.에이. 종양용해성 바이러스 및 치료 분자
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
US11542312B2 (en) 2017-06-19 2023-01-03 Medicenna Therapeutics, Inc. IL-2 superagonists in combination with anti-PD-1 antibodies
WO2019032628A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
CA3099330A1 (en) * 2018-05-02 2019-11-07 Tonix Pharma Holdings Limited Synthetic chimeric vaccinia virus
WO2020056228A1 (en) * 2018-09-14 2020-03-19 Mayo Foundation For Medical Education And Research Materials and methods for treatment with oncolytic viruses and modified car t cells
CN109234238A (zh) * 2018-09-30 2019-01-18 杭州华安单抗生物技术有限公司 细胞株及其应用、b细胞的培养体系及培养方法和抗体的制备方法
JP2022508942A (ja) * 2018-10-22 2022-01-19 アイセルキーレクス セラピューティクス エルエルシー 変異ワクシニア・ウイルスおよびその使用
MX2021013601A (es) * 2019-05-09 2021-12-10 Sator Therapeutics LLC Entrega de virus oncoliticos mediante celulas dendriticas.
CN111979204B (zh) * 2019-05-24 2023-10-13 杭州功楚生物科技有限公司 携带海绵凝集素基因的溶瘤痘苗病毒、构建方法及用途
WO2022266163A2 (en) * 2021-06-17 2022-12-22 Kalivir Immunotherapeutics, Inc. Tnfsf-l fusion proteins and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2269619A1 (en) * 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC Methods and compositions concerning poxviruses and cancer
WO2008043576A1 (en) * 2006-10-13 2008-04-17 Medigene Ag Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer

Also Published As

Publication number Publication date
WO2013038066A1 (en) 2013-03-21
FI20115914L (sv) 2013-03-17

Similar Documents

Publication Publication Date Title
FI20115914L (sv) Modifierat onkolytiskt virus
CY1123010T1 (el) Διεγερση γονιδιου τrail με μικρο μοριο απο κανονικα και ογκου κυτταρα ως αντικαρκινικη θεραπεια
CY1119960T1 (el) Μεθοδοι για την αυξηση της αποτελεσματικοτητας της folr1 θεραπειας του καρκινου
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
CY1125279T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
CY1120103T1 (el) Κλιμακωσιμο συστημα παραγωγης λεντιικου φορεα, συμβατο με βιομηχανικες φαρμακευτικες εφαρμογες
AU2017261625B2 (en) Non-natural consensus albumin binding domains
MX2018001040A (es) Moleculas de acido nucleico artificiales.
WO2012075040A3 (en) mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
MX2015012450A (es) Proceso de elaboracion escalable para producir vectores lentivirales recombinantes en un sistema de cultivo celular en suspension libre de suero.
MX356625B (es) Oligonucleotidos para elaborar un cambio en la secuencia de una molécula de ácido ribonucleico objetivo presente en una célula viva.
HK1202800A1 (en) Therapeutic uses of fibroblast growth factor 21 proteins 21
MX357803B (es) Moléculas de ácido nucleico artificiales.
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
PH12018501404A1 (en) Forms of rifaximin and uses thereof
MX346923B (es) Genes y proteinas para sintesis de alcanoil-coa.
EP2670443A4 (en) NUCLEIC ACID MOLECULES ENCODING NEW HERPES ANTIGENS, VACCINE COMPRISING THE SAME, AND METHODS OF USING SAME
MX2015002371A (es) Inhibidores bivalentes de las proteinas iap y metodos terapueticos que usan los mismos.
MX358706B (es) Moleculas de acido nucleico artificiales que comprenden un top 5´utr.
CY1114483T1 (el) Νεα ρυθμιστικα στοιχεια
MX2014010750A (es) Anticuerpos receptores del factor de crecimiento anti-epidermico condicionalmente activos y metodos de uso de los mismos.
TN2012000414A1 (en) Forms of rifaximin and uses thereof
MX2015014851A (es) Vacuna de adn que dirige wt-1 novedosa para inmunoterapia del cancer.
BR112014015016A8 (pt) Proteína homodimérica de duas cadeias de aminoácidos idênticas, cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica, célula hospedeira, método de preparação de uma proteína homodimérica, método para preparação de uma vacina, vacina e método de tratamento ou prevenção
MX369550B (es) Gen de fusion del receptor de factor de crecimiento de fibroblastos 3 (fgfr3) y medicamentos farmaceutico para tratar el mismo.

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: ONCOS THERAPEUTICS LTD.

FD Application lapsed